Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluarix immunogenicity and safety in children previously vaccinated with Pandemrix
2010-020330-26Phase 4Completed
- Sponsor
- GSK
- Start
- Jun 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Fluarix in influenza, sponsored by GSK. Primary endpoints: Humoral immune response against H1N1 at 28 days after first Fluarix dose, Safety after each influenza vaccination and 1 more. Started Jun 2010; status: completed.
02
Drugs
Fluarix
03
Conditions
influenza
Beyond the preview
Go deeper on 2010-020330-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020330-26.